Many of you use the long-acting, anticholinergic bronchodilator Spiriva for daily maintenance treatment of COPD. According to a recent study, combining Spiriva Handihaler with the Onbrez Breezhaler works better to improve lung function than just using Spiriva alone.
Onbrez is a relatively new, long-acting beta agonist bronchodilator manufactured by the drug company, Novartis. So new, in fact, it has not yet met with FDA approval in the United States. It is currently being used however, in the European Union as well as in 50 other countries. The FDA advisory committee will be discussing its approval for the US market in March of this year.
While Onbrez and Spiriva are both bronchodilators, each has a different mode of action. Both drugs open up the airways and make breathing easier for people with COPD. Combining bronchodilators of different classes is recommended by the Global Initiative for Obstructive Lung Disease (GOLD) as part of the standard treatment guidelines for COPD.
To learn more about the study, read the press release at Pharmabiz.
If you are from the European Union or another country in which Onbrez is approved and have used this drug, please share your comments about its effectiveness below.